VintaBio, which debuted in 2023 as a CDMO focused on cranking out viral vectors for cell and gene therapy production, is having its manufacturing facility and intellectual property put up for sale.
The company agreed to hand over its assets to an assignee (DSI Assignments) on Oct. 27 as part of a state legal process that insolvent or financially distressed businesses can pursue to pay off creditors rather than declaring bankruptcy in a federal court.
The assignee has now put those assets up for sale, with the pitch encompassing both intellectual property and VintaBio’s 22,500-square-foot Philadelphia production plant. The facility marks a $17 million capital investment and includes a trio of manufacturing suites, plus fill-finish capabilities and support labs, according to a DSI release.
The site, which opened in 2023 after Vintabio emerged from stealth, was developed for high-yield, high purity production of AAV8 vectors and potential applications across multiple viral vector modalities.
The VintaBio IP that is also up for sale includes the company’s VintaCells, VintaProcess and extended-harvest methodologies.
The sale comes amid a slow-down in market demand for viral vector production. The field had previously enjoyed an influx of activity as companies sought to lock down a manufacturing pinch point for making cell and gene therapies.
However, a study by Intuition Labs released in August showed that market consolidation has resulted in capacity for producing viral vectors outpacing clinical demand, resulting in sponsors having more manufacturing options but fewer financially stable partners in practice.
That overabundance resulted in companies like AmplifyBio shuttering in 2025. That same year, Thermo Fisher closed its viral vector plant in Lexington, Massachusetts.
In February, Charles River Laboratories shuttered its cell therapy CDMO site in Hanover, Maryland.
The deadline for bidding on the VintaBio assets is set for 5 p.m. ET on Dec. 15, per DSI.